PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfolliclestemcells, but minoxidil and finasteride are still the main treatments.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
PP405 is a new hair loss treatment targeting dormant hairfollicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.